First, please keep in mind that my estimate is for an increased utilization of only the 30mg and 40mg prefilled syringe dosing for inpatients only. This is not an "across the board" increase for all LMWH or of all the 30mg or 40mg dosing as some of that continues in the outpatient setting for various indications.
Most hospitals that I am familiar with initiated an educational process by late 2009 and probably rolled out order sets by late 2010, so the baseline would be right around when m-enox was approved.
Also, if this initiative is effective in preventing DVT and/or PE, there will be less usage of 1mg/kg/12hour LMWH, but this decrease utilization will be consistent with a "rounding error."
Does this address your concerns? Again, simply my stab in the dark.
Market Data 
Markets 
AI
